Skip to search formSkip to main contentSkip to account menu

EGFR Inhibitor ABT-414

Known as: ABT-414 
An epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon intravenous infusion, ABT-414 inhibits the… 
National Institutes of Health

Related topics

Related topics

2 relations
NCIt Antineoplastic Agent TerminologyReceptor Tyrosine Kinase Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
ACTR-21. A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIAL OF DEPATUXIZUMAB MAFODOTIN (ABT-414) IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AMPLIFIED (AMP) NEWLY DIAGNOSED GLIOBLASTOMA…
Approximately 50% of nGBMs harbor EGFR-amp. Depatuxizumab mafodotin (depatux-m) is an antibody drug conjugate: a monoclonal… 
2018
2018
Corneal Toxicity Induced by ABT-414 Therapy for Glioblastoma Multiforme: A Case Report
Background: To describe a case of corneal toxicity associated with the use of the epidermal growth factor receptor (EGFR… 
2017
2017
Efficacy analysis of ABT-414 with or without temozolomide (TMZ) in patients (pts) with EGFR-amplified, recurrent glioblastoma (rGBM) from a multicenter, international phase I clinical trial
2003Background: GBM is the most common malignant primary brain tumor in adults. Pts with rGBM have a poor prognosis. EGFR is… 
2016
2016
Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, as monotherapy in epidermal growth factor receptor (EGFR) amplified, recurrent glioblastoma (GBM).
2542Background: Recurrent GBM (rGBM) has dismal prognosis. Almost 50% GBM tumors harbor amplified (amp) EGFR. ABT-414 is a tumor… 
2015
2015
ABT-414 in patients with advanced solid tumors likely to overexpress the epidermal growth factor receptor (EGFR).
2510 Background: Aberrant EGFR expression and signaling has been identified as a hallmark of cancer growth and survival. ABT-414… 
2015
2015
A Phase 1 Study Evaluating ABT-414 with Temozolomide (TMZ) or Concurrent Radiotherapy (RT) and TMZ in Glioblastoma (GBM) (S43.006)
Objectives: Study objectives were evaluation of safety, PK, recommended Phase 2 dose (RP2D), and preliminary efficacy of ABT-414… 
2015
2015
ATNT-01ABT-414 MONO- OR COMBINATION THERAPY WITH TEMOZOLOMIDE (TMZ) RECHALLENGE IN PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM) AND AMPLIFIED EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR): A PHASE I STUDY
BACKGROUND: Aberrant EGFR signaling plays a vital role in GBM oncogenesis. ABT-414 is an antibody-drug conjugate with a toxic… 
2015
2015
ATNT-02DETERMINANTS OF RESPONSES AND RESISTANCE TO ABT-414: RESULTS OF NEXT-GENERATION SEQUENCING
BACKGROUND: ABT-414 is an EGFR-targeted antibody conjugated to the toxic antimicrotubule agent monomethylauristatin F. In an… 
2015
2015
2903 Identifying the correct patient (pt) population for ABT-414: Biomarker assays for epidermal growth factor receptor (EGFR) in pts with glioblastoma (GBM)
2014
2014
A phase 1 study evaluating ABT-414 in combination with temozolomide (TMZ) for subjects with recurrent or unresectable glioblastoma (GBM).
2021 Background: Patients (pts) with recurrent GBM have few treatment options and a very poor prognosis. GBM tumors often exhibit… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)